Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muthiah Manoharan

Showing results (131-140 of 172) with videos related to

Pageof 18
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 15, 2023
Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumorsShubaash Anthiya, Süleyman Can Öztürk, Hamdullah Yanik, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 18, 2021
Centyrin ligands for extrahepatic delivery of siRNADonna Klein, Shalom Goldberg, Christopher S Theile, et al.
Nature Communications|February 21, 2018
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicityMaja M Janas, Mark K Schlegel, Carole E Harbison, et al.
Nucleic Acids Research|July 16, 2021
Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivoHartmut Jahns, Nate Taneja, Jennifer L S Willoughby, et al.
Nucleic Acids Research|February 12, 2021
siRNAs containing 2'-fluorinated Northern-methanocarbacyclic (2'-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2'-F-NMC NTPsMasaaki Akabane-Nakata, Namrata D Erande, Pawan Kumar, et al.
Journal of Medicinal Chemistry|February 3, 2025
Expanding Conjugate Space of RNAi Therapeutics: Ligand at the 3' End of the Antisense Strand Achieves Uncompromised In Vivo Potency and Efficacy and Reveals Interactions with the Argonaute-2 PAZ DomainRajat S Das, Dhrubajyoti Datta, Christopher R Brown, et al.
Nucleic Acids Research|September 11, 2021
Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencingHartmut Jahns, Rohan Degaonkar, Peter Podbevsek, et al.
Chembiochem : a European Journal of Chemical Biology|March 20, 2015
Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivoKallanthottathil G Rajeev, Jayaprakash K Nair, Muthusamy Jayaraman, et al.
Nucleic Acids Research|April 17, 2026
Acyclic serinol nucleic acid modification of siRNAs overcomes seed region mediated off-target effects while maintaining potencyTyler Chickering, Joel M Harp, Yongfeng Jiang, et al.
RNA (New York, N.Y.)|February 2, 2012
Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivoDonald J Foster, Scott Barros, Rick Duncan, et al.
Pageof 18

Showing results (131-140 of 172) with videos related to

Sort By:
Pageof 18
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 15, 2023
Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumorsShubaash Anthiya, Süleyman Can Öztürk, Hamdullah Yanik, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 18, 2021
Centyrin ligands for extrahepatic delivery of siRNADonna Klein, Shalom Goldberg, Christopher S Theile, et al.
Nature Communications|February 21, 2018
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicityMaja M Janas, Mark K Schlegel, Carole E Harbison, et al.
Nucleic Acids Research|July 16, 2021
Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivoHartmut Jahns, Nate Taneja, Jennifer L S Willoughby, et al.
Nucleic Acids Research|February 12, 2021
siRNAs containing 2'-fluorinated Northern-methanocarbacyclic (2'-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2'-F-NMC NTPsMasaaki Akabane-Nakata, Namrata D Erande, Pawan Kumar, et al.
Journal of Medicinal Chemistry|February 3, 2025
Expanding Conjugate Space of RNAi Therapeutics: Ligand at the 3' End of the Antisense Strand Achieves Uncompromised In Vivo Potency and Efficacy and Reveals Interactions with the Argonaute-2 PAZ DomainRajat S Das, Dhrubajyoti Datta, Christopher R Brown, et al.
Nucleic Acids Research|September 11, 2021
Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencingHartmut Jahns, Rohan Degaonkar, Peter Podbevsek, et al.
Chembiochem : a European Journal of Chemical Biology|March 20, 2015
Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivoKallanthottathil G Rajeev, Jayaprakash K Nair, Muthusamy Jayaraman, et al.
Nucleic Acids Research|April 17, 2026
Acyclic serinol nucleic acid modification of siRNAs overcomes seed region mediated off-target effects while maintaining potencyTyler Chickering, Joel M Harp, Yongfeng Jiang, et al.
RNA (New York, N.Y.)|February 2, 2012
Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivoDonald J Foster, Scott Barros, Rick Duncan, et al.
Pageof 18